Mayne Pharma to exit Australian operations in $55.5m sale

4 minute read


The ASX-listed pharmaceutical company is selling its Australian manufacturing and commercial operations to Australian-owned Evaris Pharma as it shifts its focus entirely to the US.


The ASX-listed pharmaceutical company is selling its Australian manufacturing and commercial operations to Australian-owned Evaris Pharma as it shifts its focus entirely to the US.

This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.

End of content

No more pages to load

Log In Register ×